数据链接：
官方服务：
资源简介：
CD33 expression on AML patient samples.
应用场景：
创建时间：
2016-12-02
相关数据集
Rational biomarker development for the early and minimally invasive monitoring of AML
We investigated circulating plasma EVs miRNA from 12 AML patients versus 12 healthy donors to identify a miRNA signature as a potential biomarker for patients with AML. Overall design: Plasma samples
NIAID Data Ecosystem80
Leukemic initiation in Jam-C-deficient HSPC reveals AP-1/TNF- gene expression signature as a biomarker for AML. Leukemic initiation in Jam-C-deficient HSPC reveals AP-1/TNF- gene expression signature as a biomarker for AML
The leukemic stem cell score 17 (LSC-17) based on stemness gene expression signature is recognized as indicator of poor disease outcome in acute myeloid leukemia (AML). However, our understanding of t
NIAID Data Ecosystem30
Table1_Comprehensive analysis of PTPN family expression and prognosis in acute myeloid leukemia.DOCX
Background: Tyrosyl phosphorylation is carried out by a group of enzymes known as non-receptor protein tyrosine phosphatases (PTPNs). In the current investigation, it is hoped to shed light on the rel
NIAID Data Ecosystem10
SETD2 detection may reveal response to induction therapy and survival profile in acute myeloid leukemia patients
SET domain containing protein 2 (SETD2) involves in the progression and development of chemotherapy resistance in acute myeloid leukemia (AML). Hence, this study aimed to investigate the relationship
NIAID Data Ecosystem50
Correlations between ARHGEF6 expression and clinicopathological characteristics in AML from the TCGA cohort.
Correlations between ARHGEF6 expression and clinicopathological characteristics in AML from the TCGA cohort.
Figshare2023-04-07 更新20
